Menu
 
Home Events Consensus About  
Foundation St.Gallen Deso
Contact

15 – 18 03 2023

Austria Center Vienna

St.Gallen International Breast Cancer Conference

Welcome

We would like to express our sincere gratitude for your valuable contribution to the 18th St.Gallen International Breast Cancer Conference 2023. It brings us great pleasure to see so many delegates come together every two years to learn about the latest developments in the treatment of individuals with early breast cancer, and your presence and contribution played an integral part in making the conference a success. As per tradition, the conference concluded with an update on the widely acknowledged «St.Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer,» which will be published just a few months after the conference.

The next St. Gallen International Breast Cancer Conference will take place from 12 – 15 March 2025 in Vienna. We cordially invite you to mark this date in your agenda today. Don’t miss any news and sign up for our newsletter or join us on social media to stay informed. Once again, we would like to thank you for your participation and contribution to this important event, and we hope to see you again at the SGBCC 2025!

Save the date!

19th St.Gallen International Breast Cancer Conference 2025

Primary Therapy of Early Breast Cancer. Evidence, Controversies, Consensus

12 03 - 15 03 2025, Austria Center Vienna

Programme

15 03 2023

Wednesday
11.30 – 12.30

Industry sponsored symposium

13.00 – 14.00
Opening Ceremony

Welcome, Awards and Award Lectures

Chairs:
Michael Gnant (Austria)
Beat Thürlimann (Switzerland)
Walter Weber (Switzerland)

St.Gallen Breast Cancer Award 2023
Chairs:
Beat Thürlimann (Switzerland)
Walter Weber (Switzerland)

The St.Gallen Breast Cancer Award Lecture 2023:
The Saga of Theragnostic Biomarkers of Breast Cancer (Giuseppe Viale, Italy)

ESO Umberto Veronesi Memorial Award 2023
Chair: Alexandru Eniu (ESO)

The ESO Umberto Veronesi Memorial Award Lecture 2023:
A global approach to breast cancer management (Benjamin Anderson, WHO)

14.00 – 14.15
Short Break
14.15 – 15.30
Session 1

News in Breast Cancer Care since SGBCC 2021

Chairs:
Beat Thürlimann (Switzerland)
Tanja Spanic (Slovenia)

15 min. per lecture

Surgery of patients with early breast cancer: quo vadis? (Walter Weber, Switzerland)

Access to evidence based radiation therapy for patients with early breast cancer (Philip Poortmans, Belgium)

What’s new in systemic treatment of patients with early breast cancer (Roisin Connolly, Ireland)

Translational research priorities for patients with early breast cancer (Fabrice André, France)

Hot topics in survivorship, patient reported outcomes, and Quality of Life (Ann Partridge, USA)

15.30 – 16.00
Coffee break
15.30 – 16.15
SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.

Chair:
Emiel Rutgers (Netherlands)

Co-Chair:
Sara Brucker (Germany)

Discussants:
Stefan Aebi (Switzerland)
Meteb Al-Foheidi (KSA)
Zefei Jiang (China)
Toru Watanabe (Japan)

16.00 – 17.30
Interactive Session I

How to avoid unnecessary mastectomies – a global discussion

Chairs:
Monica Morrow (USA)
Walter Weber (Switzerland)

Panelists:
Meteb Al-Foheidi (KSA)
Denisse Bretel (Peru)
Jana de Boniface (Sweden)
Fatima Cardoso (Portugal)
Heba Gamal (Egypt)
Eun-Sook Lee (Korea)
Monica Morrow (USA)
Lori Pierce (USA)
Zhiming Shao (China)
Tanja Spanic (Slovenia)
Masakazu Toi (Japan)

17.30 – 19.00
Welcome Apéro

at the Austria Center Vienna

16 03 2023

Thursday
08.00 – 08.45

Industry sponsored symposium

09.00 – 10.00
Session 2

Genomics, Transcriptomics, ctDNA for disease monitoring and risk stratification

Chairs:
Fabrice André (France)
Meredith Regan (USA)

15 min. per lecture

ctDNA dynamics for early assessment of recurrence risk (Nicholas Turner, UK)

Molecular imaging in breast cancer (Michel van Kruchten, Netherlands)

Multi-omic machine learning prediction of treatment response (Carlos Caldas, UK)

How to assess clinical utility and clinical validity of biomarkers in clinical trials? (Meredith Regan, USA)

10.00 – 11.00
Session 3

Immunology in early breast cancer

Chairs:
Sherene Loi (Australia)
Aleix Prat (Spain)

15 min. per lecture

Understanding the anti-cancer immune response: Innate and adaptive responses to breast cancer cells (Sherene Loi, Australia)

Tumor microenvironment in early breast cancer (Carsten Denkert, Germany)

Multiplexed analysis and spatial histology to predict response (Marleen Kok, Netherlands)

The future of breast cancer immunotherapy (PD, PDL, vaccines) (Giuseppe Curigliano, Italy)

11.00 – 13.00
Lunch break
11.30 – 12.30

Industry sponsored symposium

12.45 – 13.30

Special lecture I and panel discussion

Chair:
Michael Gnant (Austria)

Panelists:
David Cameron (UK)
Heba Gamal (Egypt)
Chiun-Sheng Huang (Taiwan)

Special lecture I

The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs? (Sara Tolaney, USA)

13.30 – 14.30
Session 4

Hereditary Breast Cancer

Chairs:
Lisa Carey (USA)
Suzette Delaloge (France)

15 min. per lecture

Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk (Suzette Delaloge, France)

Local treatment in patients with high risk hereditary breast cancer (Maria Joao Cardoso, Portugal)

Management of patients harboring medium penetrance genes (Christian Singer, Austria)

Adjuvant systemic therapy for patients with germline BRCA1/2 mutations (Andrew Tutt, UK)

14.30 – 15.30
Session 5

The future treatment landscape in the adjuvant setting

Chairs:
Sibylle Loibl (Germany)
Martine Piccart (Belgium)

15 min. per lecture

Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors (Javier Cortes, Spain)

Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors? (Angela De Michele, USA)

What’s next? Antibody drug conjugates for breast cancer therapy (Cristina Saura, Spain)

Integrating new oral SERDs in the adjuvant treatment (David Cameron, UK)

15.30 – 16.00
Coffee Break
15.30 – 16.15
SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.

Chair:
Fatima Cardoso (Portugal)

Co-Chair:
Carlos Barrios (Brazil)

Discussant:
Jonas Bergh (Sweden)

16.00 – 16.45
Debate I

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Chairs:
Giuseppe Curigliano (Italy)
Michael Gnant (Austria)

Debaters:
Lisa Carey (USA)
Nadia Harbeck (Germany)

16.45 – 17.30
Interactive Session II

Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.

Chairs:
Harold Burstein (USA)
Prudence Francis (Australia)

Panelists:
Charlotte Coles (UK)
Eun-Sook Lee (Korea)
Frederique Penault-Llorca (France)
Martine Piccart (Belgium)
Cristina Saura (Spain)
Andrew Tutt (UK)

What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)

17 03 2023

Friday
09.00 – 10.00
Session 6

Tailoring breast surgery and radiotherapy

Chairs:
Jana de Boniface (Sweden)
Lori Pierce (USA)

15 min. per lecture

Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer (Charlotte Coles, UK)

Benefits and risks of oncoplastic breast-conserving surgery (Marie-Jeanne Vrancken Peeters, Netherlands)

Breast surgery after neoadjuvant therapy (Andrea V. Barrio, USA)

Breast surgery for local recurrence (Isabel Rubio, Spain)

10.00 – 11.00
Session 7

Controversies in the treatment of the axilla

Chairs:
Philip Poortmans (Belgium)
Zhiming Shao (China)

15 min. per lecture

Omission of surgical staging of the axilla (Oreste Gentilini, Italy)

Axillary surgery in the adjuvant setting (Jana de Boniface, Sweden)

Limited axillary surgery concepts to determine nodal pathologic complete response (Jörg Heil, Germany)

De-escalation of axillary radiotherapy – the time has come! (Icro Meattini, Italy)

11.00 – 13.00
Lunch break
11.00 – 11.30

Best Poster Presentation

Chair:
Beat Thürlimann (Switzerland)

11.30 – 12.30

Industry sponsored symposium

13.00 – 13.45
Debate II

Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy

Chairs:
Michael Gnant (Austria)
Philip Poortmans (Belgium)

Debaters:
Orit Kaidar-Person (Israel)
Monica Morrow (USA)

13.45 – 14.30
Interactive Session III

Controversies and uncertainties in axillary management

Chairs:
Walter Weber (Switzerland)
Bahadir Gulluoglu (Turkey)

Panelists:
Jana de Boniface (Sweden)
Oreste Gentilini (Italy)
Orit Kaidar-Person (Israel)
Eun-Sook Lee (Korea)
Monica Morrow (USA)
Philip Poortmans (Belgium)
Isabel Rubio (Spain)
Marie-Jeanne Vrancken Peeters (Netherlands)

14.30 – 14.45
Short break
14.30 – 15.15
SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.

Chair:
Elzbieta Senkus-Konefka (Poland)

Co-Chair:
Gerd Fastner (Germany)

Discussant:
Chiun-Sheng Huang (Taiwan)

14.45 – 15.45
Session 8

Optimizing treatment in patients with HER2-positive breast cancer

Chairs:
Hope S. Rugo (USA)
Masakazu Toi (Japan)

15 min. per lecture

Assessing HER2 heterogeneity (Frederique Penault-Llorca, France)

Current adjuvant and neoadjuvant approaches (Nadia Harbeck, Germany)

Emerging new treatments in HER2 positive breast cancer (Martine Piccart, Belgium)

ER positive vs ER negative: tackling diversity in HER2 positive breast cancer (Aleix Prat, Spain)

15.45 – 16.45
Session 9

Optimizing treatment in patients with triple negative breast cancer

Chairs:
Lisa Carey (USA)
Zefei Jiang (China)

15 min. per lecture

Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer (Hope S. Rugo, USA)

Optimal systemic therapy for residual disease in TNBC (Sibylle Loibl, Germany)

Tackling triple negative histological subtypes in early breast cancer (Jorge Reis Filho, USA)

Can we de-escalate immunotherapy and chemotherapy in TNBC? (Hervè Bonnefoi, France)

16.45 – 17.30
Debate III

If you achieve pCR after neoadjuvant, do you need adjuvant therapy?

Chairs:
Giuseppe Curigliano (Italy)
Sherene Loi (Australia)

Debaters:
Sibylle Loibl (Germany)
Steven Chia (Canada)

17.30 – 17.45
Short break
17.45 – 18.45

Industry sponsored symposium

18 03 2023

Saturday
09.00 – 10.00
Session 10

Global Prespective on breast cancer treatment

Chairs:
Carlos Barrios (Brazil)
Binghe Xu (China)

15 min. per lecture

Breast cancer treatment and research from a global perspective (Benjamin Anderson, World Health Organization)

Perspective from Asia (Binghe Xu, China)

Perspective from Africa (Heba Gamal, Egypt)

Perspective from Latin America (Denisse Bretel, Peru)

10.00 – 11.00
Session 11

Optimizing treatment in patients with HR positive breast cancer

Chair:
Stefan Aebi (Switzerland)

15 min. per lecture

What to do when there are many options? Integrating Olaparib in BRCA-associated ER positive tumors (Sara Brucker, Germany)

Pre-menopausal: Who needs chemotherapy in the (neo)adjuvant setting? (Prudence Francis, Australia)

Can we omit adjuvant endocrine therapy? (Fatima Cardoso, Portugal)

Duration of endocrine therapy in early breast cancer (Jens Huober, Switzerland)

11.00 – 11.15
Short break
11.15 – 11.45
Debate IV

Surgery of the primary for stage IV disease

Chairs:
William Gradishar (USA)
Bahadir Gulluoglu (Turkey)

Presenting data:
William Gradishar (USA)

Debaters:
Rajendra Badwe (India)
Florian Fitzal (Austria)

12.00 – 12.30
Lunch break
12.30 – 14.30
St.Gallen International Consensus Session I

St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023

Seeking consensus on evidence and opinions

Moderator and Scientific Secretary:
Harold Burstein (USA)
Giuseppe Curigliano (Italy)

14.30 – 14.45
Short break
14.45 – 16.45
St.Gallen International Consensus Session II

St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023

Seeking consensus on evidence and opinions

Moderator and Scientific Secretary:
Harold Burstein (USA)
Giuseppe Curigliano (Italy)

16.45 – 17.00
Farewell

Consensus

St.Gallen International Consensus on the primary treatment of individuals with breast cancer

As per tradition, the SGBCC 2023 concluded with an update on the widely acknowledged «St.Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer.» The list of the St.Gallen International Breast Cancer Consensus Panel 2023 can be found here.

Publication 2023
The anticipated 2023 edition of the St.Gallen International Consensus Guidelines is coming up soon. Stay tuned for its release in the prestigious Annals of Oncology and be at the forefront of cutting-edge care.

Chairs

Conference co-chairs

Univ. Prof. Dr. Michael Gnant
Medical University of Vienna/Austria

Prof. Dr. med. Beat Thürlimann
Breast Centre, Kantonsspital St.Gallen/Switzerland and SwissBreastCare, Bethanienspital, Zurich/Switzerland

Prof. Dr. Walter Weber
University Hospital Basel/Switzerland

Scientific Programme-Planning Committee

Harold Burstein, Boston/USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Sibylle Loibl, Neu-Isenburg/Germany
Philip Poortmans, Antwerp/Belgium
Meredith Regan, Boston/USA
Hans-Joerg Senn (†), St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, New Haven/USA

Conference founder and honorary chair

Prof. Dr. med. Hans-Joerg Senn
(* 28 March 1934, † 13 January 2023), Foundation St.Gallen Oncology Conferences (SONK),
St.Gallen/Switzerland

Faculty

Conflict of interest statement

All faculty members of the scientific programme have submitted a conflict of interest statement.
The summary of all statements is available here.

Aebi Stephan
Luzerner Kantonsspital, Lucerne Cantonal Hospital / Switzerland

Al-Foheidi Meteb
Princess Noorah Oncology Center, National Guard Health Affairs / KSA

Anderson Benjamin
WHO / Switzerland

André Fabrice
Gustave Roussy / France

Anikusko Mikola
Kyiv City Clinical Oncology Center / Ukraine

Badwe Rajendra
Dr. E. Borges Marg, Parel, Tata Memorial Centre / India

Barrio Andrea V.
Memorial Sloan Kettering Cancer Center / USA

Barrios Carlos
LACOG – Latin American Cooperative Oncology Group, Lacog – Oncoclínicas Group / Brazil

Berg Jonas
Karolinska Institutet and University Hospital / Sweden

Bonnefoi Hervé
Institut Bergonie Unicancer / France

Bretel Morales Denisse
GECOPERU – Medical Direction, Gecoperu / Peru

Brucker Sara
Tuebingen University Women’s Hospital / Germany

Burstein Harold J.
Dana-Farber Cancer Institute / USA

Caldas Carlos
Cancer Research UK Cambridge Institute, University Of Cambrige / UK

Cameron David
Edinburgh Cancer Research, The University of Edinburgh, The University Of Edinburgh / UK

Cardoso Fatima
Champalimaud Cancer Center / Portugal

Cardoso Maria Joao
Champalimaud Foundation Breast Unit / Portugal

Carey Lisa
Lineberger Comprehensive Cancer Center / USA

Chia Steven
BC Cancer, Vancouver Cancer Centre, BC Cancer – Vancouver Centre / Canada

Coles Charlotte
University of Cambridge / UK

Connolly Roisin
Cancer Research at UCC and Cork University Hospital / Ireland

Cortes Javier
International Breast Cancer Center, IBCC / Spain

Curigliano Giuseppe
Istituto Europeo di Oncologia, IRCCS / Italy

de Boniface Jana
Capio St. Göran’s Hospital, Capio St. Göran’s Hospital And Karolinska Institutet / Sweden

Delaloge Suzette
Gustave Roussy / France

DeMichele Angela
University of Pennsylvania / USA

Denkert Carsten
Universitätsklinikum Griessen und Marburg, Philipps-University Marburg / Germany

Fastner Gerd
Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg / Austria

Fitzal Florian
Medical University of Vienna, Medical University Vienna / Austria

Francis Prudence
Peter MacCallum Cancer Centre, De, Peter MacCallum Cancer Centre / Australia

Gamal Heba
National Cancer Institute, Cairo University / Egypt

Gentilini Oreste
S.Raffaele University and Research Hospital, San Raffaele University and Research Hospital / Italy

Gnant Michael
Medical University Of Vienna – ABCSG / Austria

Gradishar William
NCCN Northwestern University Feinberg School of Medicine, Nccn/northwestern University / USA

Gulluoglu Bahadir
Marmara Universiy of Medicine, Marmara University School Of Medicine / Turkey

Harbeck Nadia
Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of Munich / Germany

Heil Jörg
Breast Unit Heidelberg / Germany

Huang Chiun-Sheng Huang
National Taiwan University Hospital / Taiwan

Huober Jens
Cantonal Hospital St.Gallen, Kantonsspital St.Gallen, Brustzentrum / Switzerland

Jiang Zefei
Fifth Medical Center of Chinese PLA General Hospital Beijing / China

Kaidar-Person Orit
Sheba Tel Hashomer, Oncology Institute, Sheba Medical Center / Israel

Kok Marleen
Netherlands cancer institute, Netherlands Cancer Institute / Netherlands

Lee Eun-Sook
National Cancer Center / Korea

Loi Sherene
Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre / Australia

Loibl Sibylle
GBG Forschungs GmbH, Gbg Forschungs Gmbh / Germany

Martin Miguel
Hospital Gregorio Marañon / Spain

Meattini Icro
University of Florence, University Of Florence / Italy

Morrow Monica
Memorial Sloan Kettering Cancer Center / USA

Partridge Ann
Dana Farber Cancer Institut / USA

Penault-Llorca Frederique
Centre Jean Perrin, centre Jean Perrin UNICANCER / France

Piccart Martine
Institut Jules Bordet, Institut Jules Bordet / Belgium

Pierce Lori
University of Michigan/, University Of Michigan / USA

Poortmans Philip
Iridium Netwerk & University Of Antwerp / Belgium

Prat Aleix
August Pi i Sunyer Biomedical Research Institute / Spain

Regan Meredith
Dana-Farber Cancer Institute,, Dana-farber Cancer Institute / USA

Reis-Filho Jorge
Memorial Sloan Kettering Cancer Center,, Memorial Sloan Kettering Cancer Center / USA

Rubio Isabel
Clinica Universidad de Navarra, Clinica Universidad De Navarra / Spain

Rugo Hope
University of California Comprehensive Cancer Center, Department of Medicine, Ucsf Helen Diller Family Comprehensive Cancer Center / USA

Rutgers Emiel
Netherlands Cancer Institute/Dept. of Surgery / Netherlands

Saura Cristina
Vall d’Hebron University Hospital/ Vall D’Hebron Institute of Oncology (VHIO), Vall D’hebrón University Hospital / Spain

Senkus Elzbieta
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Department of Oncology and Radiotherapy, Medical University of Gdańsk / Poland

Shao Zhiming
Fudan University Cancer Hospital/Department of Breast Surgery / China

Singer Christian
Medical University of Vienna, Medical University/Center for Breast Health /Austria

Spanic Tanja
Europa Donna / Slovenia

Thuerlimann Beat
Breast Center St.Gallen and SwissBreastCare Zürich / Switzerland

Toi Masakazu
Kyoto University Hospital / Japan

Tolaney Sara
Harvard Medcial School / Dana-Farber Cancer Institute, Dana-Farber Cancer Institute / USA

Turner Nicholas
Royal Marsden Hospital, Icr / UK

Tutt Andrew
The Institute of Cancer Research / Breast Cancer Research / UK

van Kruchten Michel
University Medical Center of Groningen / Netherlands

Viale Giuseppe
European Institute of Oncology Milan / Italy

Vrancken Peeters Marie-Jeanne
Netherlands cancer institute – antoni van leeuwenhoek, Netherlands Cancer Institute – Antoni Van Leeuwenhoek / Netherlands

Watanabe Toru
Hamamatsu Oncology Center / Japan

Weber Walter
University Hospital Basel / Switzerland

Wildiers Hans
University Hospitals Leuven / Belium

Xu Binghe
Cancer Hospital, Chinese Academy of Medical Sciences / China

Abstracts

accepted abstract
The list of all accepted abstracts can be found here..

book of abstracts
All accepted abstracts have been published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. Click here to access the journal.

Best Poster Awards 2023

A renowned reviewing team honours the three best poster abstracts with the St.Gallen Oncology Conferences Best Poster Award 2023. The awards were presented at the SGBCC 2023 on Wednesday, 15 March 2023.

Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world

The SGBCC 2023 was a great success, bringing together leading experts in the field of breast cancer from around the world to share the latest research, best practices, and insights. The conference featured a range of engaging sessions, including keynote lectures, panel discussions, and interactive workshops, covering a broad range of topics related to breast cancer.

One of the highlights of the conference was the SGBCC Academy, which offered a series of lectures on the most important topics in early breast cancer care, delivered by the panelists of the St. Gallen Consensus. Attendees had the opportunity to access these lectures via the virtual conference platform and participate in daily SGBCC Academy sessions, where they could ask follow-up questions and engage in further discussions on the most pressing issues in patient care.

Looking ahead, we are excited to continue providing exceptional educational opportunities to our attendees. We invite you to mark your calendars for the next St. Gallen International Breast Cancer Conference, which will take place in Vienna from 12 – 15 March 2025. Stay tuned for updates and announcements about the program and speakers, and we look forward to seeing you there.

Awards

St.Gallen International Breast Cancer Award Winner 2023

The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) honors Professor Giuseppe Viale for his extraordinary contribution in research and practice development in the treatment of individuals with breast cancer with the “St.Gallen International Breast Cancer Award 2023“, which was presented during the SGBCC 2023 on 15 March 2023.

Prof. Giuseppe Viale

European Institute of Oncology IRCCS, Milan / Italy

St.Gallen Oncology Conferences (SONK) is privileged to count on Prof. Giuseppe Viale as an active contributor and supporter of the St.Gallen International Breast Cancer Conference and Consensus Guidelines. He is the first pathologist to receive this Award. He added his scientific and professional perspective to provide truly interdisciplinary discussions for the benefit of the best treatment of individuals with early breast cancer. With the St.Gallen Breast Cancer Award 2023, the Foundation St.Gallen Oncology Conferences (SONK) wishes to honour Giuseppe Viale for his extraordinary contributions to breast cancer science.

Former St.Gallen International Breast Cancer Award Winners

2021: Prof. Philip Poortmans, Wilrijk-Antwerp/BE

2019: Prof. Monica Morrow, New York/USA

2017: Prof. Martine Piccart-Gebhart, Brussels/BE

2015: Prof. Alan Coates, Cennential Park/AUS

2013: Prof. Aron Goldhirsch, Lugano/CH + Milano/IT

2011: Prof. V. Craig Jordan, Washington, DC/USA

2009: Prof. Richard Gelber, Boston, MA/USA

2007: Prof. Michael Baum, London/UK

2005: Prof. Umberto Veronesi, Milano/IT

2003: Dr. Gianni Bonadonna, Milano/IT and Dr. Bernard Fisher, Pittsburg, PA/USA

Webcasts

We hope that the recordings of the 18th St.Gallen International Breast Cancer Conference 2023 will help you further enhance your knowledge and understanding of the latest developments in the field of breast cancer. Thank you for being a part of SGBCC 2023!

Opening Ceremony: Welcome, Awards and Award Lectures

Chairs: Michael Gnant (Austria), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

The St.Gallen Breast Cancer Award Lecture 2023:
The Saga of Theragnostic Biomarkers of Breast Cancer
Giuseppe Viale, Italy

The ESO Umberto Veronesi Memorial Award Lecture 2023:
A global approach to breast cancer management
Benjamin Anderson, WHO

Session 1: News in breast cancer care since St. Gallen 2021 / Best Poster Awards 2023

Surgery of patients with early breast cancer: Quo vadis?
Walter Weber, Switzerland

Access to evidence based radiation therapy for patients with early breast cancer
Philip Poortmans, Belgium

What’s new in systemic treatment of patients with early breast cancer
Roisin Connolly, Ireland

Translational research priorities for patients with early breast cancer
Fabrice André, France

Hot topics in survivorship, patient reported outcomes, and Quality of Life
Ann Partridge, USA

Session 2: Genomics, Transcriptomics, ctDNA for disease monitoring and risk stratification

ctDNA dynamics for early assessment of recurrence risk
Nicholas Turner, UK

Molecular imaging in breast cancer
Michel van Kruchten, Netherlands

Webcast not available: Multi-omic machine learning prediction of treatment response
Carlos Caldas, UK

How to assess clinical utility and clinical validity of biomarkers in clinical trials?
Meredith Regan, USA

Session 3: Immunology in early breast cancer

Understanding the anti-cancer immune response: Innate and adaptive responses to breast cancer cells
Sherene Loi, Australia

Tumor microenvironment in early breast cancer
Carsten Denkert, Germany

Multiplexed analysis and spatial histology to predict response
Marleen Kok, Netherlands

The future of breast cancer immunotherapy (PD, PDL, vaccines)
Giuseppe Curigliano, Italy

Session 4: Hereditary Breast Cancer

Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk Suzette Delaloge, France

Local treatment in patients with high risk hereditary breast cancer
Maria Joao Cardoso, Portugal

Management of patients harboring medium penetrance genes
Christian Singer, Austria

Adjuvant systemic therapy for patients with germline BRCA1/2 mutations
Andrew Tutt, UK

Session 5: The future treatment landscape in the adjuvant setting

Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors Javier Cortes, Spain

Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors?
Angela De Michele, USA

What’s next? Antibody drug conjugates for breast cancer therapy
Cristina Saura, Spain

Integrating new oral SERDs in the adjuvant treatment
David Cameron, UK

Session 6: Tailoring breast surgery and radiotherapy

Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer
Charlotte Coles, UK

Benefits and risks of oncoplastic breast-conserving surgery
Marie-Jeanne Vrancken Peeters, Netherlands

Breast surgery after neoadjuvant therapy
Andrea V. Barrio, USA

Breast surgery for local recurrence
Isabel Rubio, Spain

Session 7: Controversies in the treatment of the axilla

Omission of surgical staging of the axilla
Oreste Gentilini, Italy

Axillary surgery in the adjuvant setting
Jana de Boniface, Sweden

Limited axillary surgery concepts to determine nodal pathologic complete response
Jörg Heil, Germany

De-escalation of axillary radiotherapy – the time has come!
Icro Meattini, Italy

Session 8: Optimizing treatment in patients with HER2-positive breast cancer

Assessing HER2 heterogeneity
Frederique Penault-Llorca, France

Current adjuvant and neoadjuvant approaches
Nadia Harbeck, Germany

Emerging new treatments in HER2 positive breast cancer
Martine Piccart, Belgium

ER positive vs ER negative: tackling diversity in HER2 positive breast cancer
Aleix Prat, Spain

Session 9: Optimizing treatment in patients with triple negative breast cancer

Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer Hope S. Rugo, USA

Optimal systemic therapy for residual disease in TNBC
Sibylle Loibl, Germany

Tackling triple negative histological subtypes in early breast cancer
Jorge Reis Filho, USA

Can we de-escalate immunotherapy and chemotherapy in TNBC?
Hervè Bonnefoi, France

Session 10: Global Prespective on breast cancer treatment

Breast cancer treatment and research from a global perspective
Benjamin Anderson, World Health Organization

Perspective from Asia
Binghe Xu, China

Perspective from Africa
Heba Gamal, Egypt

Perspective from Latin America
Denisse Bretel, Peru

Session 11: Optimizing treatment in patients with HR positive breast cancer

What to do when there are many options? Integrating Olaparib in BRCA-associated ER positive tumors Sara Brucker, Germany

Pre-menopausal: Who needs chemotherapy in the (neo)adjuvant setting?
Prudence Francis, Australia

Can we omit adjuvant endocrine therapy?
Fatima Cardoso, Portugal

Duration of endocrine therapy in early breast cancer
Jens Huober, Switzerland

Interactive Session I: How to avoid unnecessary mastectomies – a global discussion

Interactive Session II: Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.

What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)

Interactive Session III: Controversies and uncertainties in axillary management

Debate I: Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Debate II: Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy

Debate III: If you achieve pCR after neoadjuvant, do you need adjuvant therapy?

Debate IV: Surgery of the primary for stage IV disease

Special lecture I and panel discussion

Special lecture I
The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs?
Sara Tolaney, USA

SGBCC Academy – on-demand lectures

Stefan Aebi: Endocrine therapies in early breast cancer

Meteb Al-Foheidi: Immunotherapy for early breast cancer – who benefits?

Carlos Barrios: Adequate treatment for early breast cancer in LMIC?

Jonas Bergh: Chemotherapy in early breast cancer – who benefits?

Sara Brucker: Early Detection, Diagnosis of Breast Cancer, quality control and Public Health Aspects

Fatima Cardoso: The importance of defining standards of care for breast cancer

Gerd Fastner: Modern radiotherapy for early breast cancer

Chiun-Sheng Huang (ROC): Preop MRI: helpful or dangerous for the breast surgeon?

Miguel Martin: New drugs on the horizon for early breast cancer

Emiel Rutgers: Breast Surgery Standards in 2023

Elzbieta Senkus-Konefka: Overtreatment in early breast cancer – who is at risk?

Masakazu Toi: Luminal B-like cancers and neoadjuvant systemic therapy – who benefits

Toru Watanabe: Gene signatures – who benefits?

Hans Wildiers: Systemic therapy in older persons for early breast cancer

Jiang Zefei: CDK4/6 Inhibition in early breast cancer – who benefits

SGBCC Satellite Symposium – Novartis

The Rise of CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: Impact For Patients

Sponsors & Partners

We thank our sponsors and partners who support the 18th St.Gallen International Breast Cancer Conference 2023.

Co-Operating Partners

Sponsors and Exhibitors

Promotional Partners

Satellite Symposia

15 03 2023

Wednesday
11.30 – 12.30
Exact Sciences

Improve patient care with genomic testing to tailor adjuvant systemic treatment in early HR+, HER2- breast cancer

  • Welcome + opening remarks – Valentina Guarneri (Italy)
  • Genomic testing – where do we stand in terms of clinical evidence? – Valentina Guarneri (Italy)
  • Identifying patients for Oncotype DX® testing in my clinical practice – Christos Markopoulos (Greece)
  • Patient’s awareness and understanding of genomic testing– Richard Simcock (UK)
  • Panel discussion and Q+A

16 03 2023

Thursday
08.00 – 08.45
Industry session organized by Medscape Oncology Global Supported by an independent educational grant from Lilly

Conceptualizing Guidelines to Manage Patients with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

Welcome and Introductions – Sara Tolaney (United States)

  • Understanding Hormone Receptor-Positive, HER2-Negative Early Breast Cancer Treatment Guidelines – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • What If: A Case Review Exploring Clinical Decision-Making and Patient Management – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • Managing Adjuvant Therapy – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • Q&A – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)

16 03 2023

Thursday
11.30 – 12.30
Novartis

The Rise of CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: Impact For Patients
Chair: Peter A. Fasching (Germany)

Faculty: Eva Ciruelos (Spain)

  • Welcome and Introduction – Peter A. Fasching (Germany)
  • Unmet need and CDK4/6 inhibitors in HR+/HER2− early breast cancer – Eva Ciruelos (Spain)
  • QOL and treatment adherence in the adjuvant setting – Peter A. Fasching (Germany)
  • Closing and Key Takeaways – Peter A. Fasching (Germany)
  • Live Q&A – All

17 03 2023

Friday
11.30 – 12.30
Daiichi-Sankyo

Advances in HER2-expressing breast cancer treatment with antibody-drug conjugates (ADCs): From metastatic to early disease

Chair: Giuseppe Curigliano (Italy)

  • Welcome and introduction – Giuseppe Curigliano (Italy)
  • How next-generation ADCs impact outcomes in HER2-expressing metastatic breast cancer – Barbara Pistilli (France)
  • Translating clinical experience with ADCs from HER2-positive metastatic breast cancer into the early disease setting – Javier Cortés (Spain)
  • Expanding the use of ADCs in HER2-low early breast cancer: What are the key considerations? – Nadia Harbeck (Germany)
  • Panel discussion – All faculty
  • Wrap up and close – Giuseppe Curigliano (Italy)

17 03 2023

Friday
17.45 – 18.45
AstraZeneca

Solving the puzzle: Tailoring treatment options in early breast cancer

  • Welcome and introductions – Nadia Harbeck (Germany)
  • Building on the biology: What has changed in the understanding of early breast cancer? – Nadia Harbeck (Germany)
  • Sequencing in the spotlight: Making sense of new treatment options – Andrew Tutt
  • Completing the picture: Multidisciplinary insights for the treatment of patients with eBC – Peter Dubsky, Carlos Barrios
  • Panel discussion – All faculty
  • Meeting close – Nadia Harbeck (Germany)